J&J to unload Indian consumer brands; Omega taps new U.K. agency; Bayer moves media-buying business;

> Johnson & Johnson ($JNJ) is selling the Indian rights to two consumer brands, Savlon antiseptic soap and Shower to Shower talcum powder, domestic media reports. Report

> Omega Pharma, currently in the process of selling itself, tapped a new agency to handle its U.K. and Ireland accounts; The Corner nabbed the business. Report

> Bayer moved a $11 million media account in Australia from Mediacom to PHD after a global review; worldwide, Mediacom kept four markets and PHD ended up with the other four, including Australia, Mumbrella says. Report

> ViiiV Healthcare expanded its campaign for HIV prevention and treatment in the U.S. South, funding grassroots outreach projects worth more than $2.8 million. Report

> Big Pharma companies are eyeing government contracts in Brazil, wooed by the market share guarantees offered under the new partnerships. Report

And Finally... Sanofi ($SNY) and Regeneron ($REGN) said they started a new study of their experimental drug dupilumab in atopic dermatitis. Release

Suggested Articles

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opidivo has broken through with two potentially practice-changing trials.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.